Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine + ropivacaine spray for prevention of postoperative sore throat after double-lumen intubation
ChiCTR2600124322Phase 4Not yet recruiting
- Sponsor
- Army Medical University
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Post-extubation sore throat (POST) and dysphonia comparing Dexmedetomidine + ropivacaine spray, Ropivacaine spray and Normal saline spray placebo (3 arms). Primary endpoint: Incidence of sore throat at 24 hours after extubation. Planned start May 2026; status: not yet recruiting.
02
Drugs
dexmedetomidineropivacaine
03
Conditions
Post-extubation sore throat (POST)dysphonia
Beyond the preview
Go deeper on ChiCTR2600124322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124322.